<li>acebutolol<p>acebutolol and digoxin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>acebutolol increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor. Enhanced bradycardia.</p></li><li>aceclofenac<p>aceclofenac and digoxin both increase  serum potassium. Use Caution/Monitor.</p></li><li>acemetacin<p>acemetacin and digoxin both increase  serum potassium. Use Caution/Monitor.</p></li><li>activated charcoal<p>activated charcoal decreases levels of digoxin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>albuterol<p>digoxin increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>alprazolam<p>alprazolam increases levels of digoxin by unknown mechanism. Use Caution/Monitor.</p></li><li>amikacin<p>amikacin will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>amiloride<p>amiloride and digoxin both increase  serum potassium. Modify Therapy/Monitor Closely.</p></li><li>anticholinergic/sedative combos<p>anticholinergic/sedative combos increases levels of digoxin by unspecified interaction mechanism. Use Caution/Monitor.</p></li><li>arformoterol<p>digoxin increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>aspirin<p>aspirin and digoxin both increase  serum potassium. Use Caution/Monitor.</p></li><li>aspirin rectal<p>aspirin rectal and digoxin both increase  serum potassium. Use Caution/Monitor.</p></li><li>aspirin/citric acid/sodium bicarbonate<p>aspirin/citric acid/sodium bicarbonate and digoxin both increase  serum potassium. Use Caution/Monitor.</p></li><li>atazanavir<p>atazanavir increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of AV block.</p></li><li>atenolol<p>atenolol and digoxin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>atenolol increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor. Enhanced bradycardia.</p></li><li>atorvastatin<p>atorvastatin will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>atropine<p>atropine increases levels of digoxin by unknown mechanism. Use Caution/Monitor.</p></li><li>atropine iv/im<p>atropine iv/im increases levels of digoxin by unknown mechanism. Use Caution/Monitor.</p></li><li>aztreonam<p>aztreonam will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>bambuterol<p>digoxin increases and bambuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>benazepril<p>benazepril increases levels of digoxin by unspecified interaction mechanism. Use Caution/Monitor.</p></li><li>bendroflumethiazide<p>digoxin increases and bendroflumethiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>bendroflumethiazide increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor. Hypokalemia increases digoxin effects.</p></li><li>betaxolol<p>betaxolol and digoxin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>betaxolol increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor. Enhanced bradycardia.</p></li><li>bisoprolol<p>bisoprolol and digoxin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>bisoprolol increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor. Enhanced bradycardia.</p></li><li>boceprevir<p>boceprevir increases levels of digoxin by Other (see comment). Use Caution/Monitor. 
Comment: Digoxin concentrations may be increased with boceprevir. Use the lowest dose initially with careful titration and monitoring of serum digoxin concentrations.</p></li><li>bosutinib<p>bosutinib increases levels of digoxin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>brimonidine<p>brimonidine increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>bumetanide<p>digoxin increases and bumetanide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>bumetanide increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor. Hypokalemia increases digoxin effects.</p></li><li>calcifediol<p>calcifediol, digoxin. Other (see comment). Modify Therapy/Monitor Closely. 
Comment: Calcifediol may cause hypercalcemia which would increase the risk of digitalis toxicity. Monitor both serum calcium levels and for signs and symptoms of digitalis toxicity.</p></li><li>calcium acetate<p>calcium acetate increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>calcium carbonate<p>calcium carbonate increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>calcium chloride<p>calcium chloride increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>calcium citrate<p>calcium citrate increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>calcium gluconate<p>calcium gluconate increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>canagliflozin<p>canagliflozin increases levels of digoxin by unspecified interaction mechanism. Modify Therapy/Monitor Closely. Digoxin AUC and peak serum concentration increased when coadministered with canagliflozin.</p></li><li>candesartan<p>candesartan and digoxin both increase  serum potassium. Use Caution/Monitor.</p></li><li>captopril<p>captopril increases levels of digoxin by unspecified interaction mechanism. Use Caution/Monitor.</p></li><li>carbenoxolone<p>digoxin increases and carbenoxolone decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>carmustine<p>carmustine decreases levels of digoxin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. It is prudent to closely monitor patients for loss of clinical efficacy of digoxin while receiving antineoplastic therapy.</p></li><li>carvedilol<p>carvedilol and digoxin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>carvedilol increases levels of digoxin by enhancing GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>carvedilol increases levels of digoxin by decreasing renal clearance. Use Caution/Monitor.<span><br><br></span>carvedilol increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor. Enhanced bradycardia.</p></li><li>cefadroxil<p>cefadroxil will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>cefamandole<p>cefamandole will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>cefpirome<p>cefpirome will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>cefpodoxime<p>cefpodoxime will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>ceftizoxime<p>ceftizoxime will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>celecoxib<p>celecoxib and digoxin both increase  serum potassium. Use Caution/Monitor.</p></li><li>celiprolol<p>celiprolol and digoxin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>celiprolol increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor. Enhanced bradycardia.</p></li><li>cephalexin<p>cephalexin will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>chlorhexidine oral<p>chlorhexidine oral will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>chlorothiazide<p>digoxin increases and chlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>chlorothiazide increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor. Hypokalemia increases digoxin effects.</p></li><li>chlorthalidone<p>digoxin increases and chlorthalidone decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>chlorthalidone increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor. Hypokalemia increases digoxin effects.</p></li><li>cholestyramine<p>cholestyramine decreases levels of digoxin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>choline magnesium trisalicylate<p>choline magnesium trisalicylate and digoxin both increase  serum potassium. Use Caution/Monitor.</p></li><li>clarithromycin<p>clarithromycin will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>clindamycin<p>clindamycin will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>clotrimazole<p>clotrimazole will decrease the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>cobicistat<p>cobicistat will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Titrate digoxin dose and monitor digoxin serum concentrations</p></li><li>colestipol<p>colestipol decreases levels of digoxin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>conivaptan<p>conivaptan increases levels of digoxin by decreasing metabolism. Use Caution/Monitor.</p></li><li>crizotinib<p>crizotinib increases levels of digoxin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration of crizotinib with CYP3A substrates with narrow therapeutic indices should be avoided.<span><br><br></span>crizotinib increases levels of digoxin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>cyclopenthiazide<p>digoxin increases and cyclopenthiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>cyclopenthiazide increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor. Hypokalemia increases digoxin effects.</p></li><li>cyclophosphamide<p>cyclophosphamide decreases levels of digoxin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>cyclosporine<p>cyclosporine will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>cytarabine<p>cytarabine decreases levels of digoxin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Cytarabine may decrease digoxin absorption even several days after stopping chemotherapy. Digoxin capsules and digitoxin do not appear to be affected. .</p></li><li>daclatasvir<p>daclatasvir will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Patients already receiving daclatasvir initiating digoxin: Use lowest appropriate digoxin dosage. Patients already receiving digoxin prior to initiating daclatasvir: Measure serum digoxin concentrations before initiating daclatasvir; reduce digoxin concentrations by decreasing digoxin dose ~30-50% or by modifying the dosing frequency. For each of the above described situations, monitor digoxin levels and adjust dose if needed.<span><br><br></span>daclatasvir will increase the level or effect of digoxin by  Other (see comment). Use Caution/Monitor. Daclatasvir inhibits OATP1B1, OATP1B3, and BCRP. Caution if coadministered with drugs that are substrates of these transporters. Patients already receiving daclatasvir initiating digoxin: Use lowest appropriate digoxin dosage. Patients already receiving digoxin prior to initiating daclatasvir: Measure serum digoxin concentrations before initiating daclatasvir; reduce digoxin concentrations by decreasing digoxin dose ~30-50% or by modifying the dosing frequency. For each of the above described situations, monitor digoxin levels and adjust dose if needed.</p></li><li>dapsone<p>dapsone will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>darifenacin<p>darifenacin increases levels of digoxin by unspecified interaction mechanism. Use Caution/Monitor.</p></li><li>demeclocycline<p>demeclocycline will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>dexlansoprazole<p>dexlansoprazole increases toxicity of digoxin by Other (see comment). Use Caution/Monitor. 
Comment: Prolonged use of PPIs may cause hypomagnesemia and increase risk for digoxin toxicity.</p></li><li>dichlorphenamide<p>dichlorphenamide and digoxin both decrease  serum potassium. Use Caution/Monitor.</p></li><li>diclofenac<p>diclofenac and digoxin both increase  serum potassium. Use Caution/Monitor.</p></li><li>diflunisal<p>diflunisal and digoxin both increase  serum potassium. Use Caution/Monitor.</p></li><li>diltiazem<p>diltiazem will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.<span><br><br></span>digoxin will increase the level or effect of diltiazem by  basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>dobutamine<p>digoxin increases and dobutamine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>dopexamine<p>digoxin increases and dopexamine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>doripenem<p>doripenem will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>doxorubicin<p>doxorubicin decreases levels of digoxin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>doxorubicin liposomal<p>doxorubicin liposomal decreases levels of digoxin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>doxycycline<p>doxycycline will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>dronedarone<p>dronedarone will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. If coadministered, consider reducing digoxin dose. Closely monitor serum digoxin levels and observe for digoxin toxicity.</p></li><li>drospirenone<p>drospirenone and digoxin both increase  serum potassium. Modify Therapy/Monitor Closely.</p></li><li>dulaglutide<p>dulaglutide, digoxin. Other (see comment). Use Caution/Monitor. 
Comment: Dulaglutide slows gastric emptying and may impact absorption of concomitantly administered oral medications; be particularly cautious when coadministered with drugs that have a narrow therapeutic index.</p></li><li>eliglustat<p>eliglustat increases levels of digoxin by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Measure digoxin levels before initiating eliglustat and reduce digoxin dose by 30%; continue to monitor digoxin levels and adjust dose accordingly.</p></li><li>elvitegravir/cobicistat/emtricitabine/tenofovir df<p>elvitegravir/cobicistat/emtricitabine/tenofovir df increases levels of digoxin by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Digoxin is a substrate for P-gp transport; cobicistat inhibits P-gp transport; initiate digoxin at low dose and carefully titrate.</p></li><li>enalapril<p>enalapril increases levels of digoxin by unspecified interaction mechanism. Use Caution/Monitor.</p></li><li>ephedrine<p>digoxin increases and ephedrine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>ephedrine (pulmonary)<p>digoxin increases and ephedrine (pulmonary) decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.  .</p></li><li>epinephrine<p>digoxin increases and epinephrine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>epinephrine racemic<p>digoxin increases and epinephrine racemic decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>eprosartan<p>eprosartan and digoxin both increase  serum potassium. Use Caution/Monitor.</p></li><li>eribulin<p>eribulin will decrease the level or effect of digoxin by  Other (see comment). Use Caution/Monitor. Antineoplastic agents may decrease absorption of digoxin; monitor patients for therapeutic efficacy.</p></li><li>ertapenem<p>ertapenem will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>erythromycin base<p>erythromycin base will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>erythromycin ethylsuccinate<p>erythromycin ethylsuccinate will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>erythromycin lactobionate<p>erythromycin lactobionate will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>erythromycin stearate<p>erythromycin stearate will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>esmolol<p>esmolol and digoxin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>esmolol increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor. Enhanced bradycardia.</p></li><li>esomeprazole<p>esomeprazole increases toxicity of digoxin by Other (see comment). Use Caution/Monitor. 
Comment: Prolonged use of PPIs may cause hypomagnesemia and increase risk for digoxin toxicity.</p></li><li>ethacrynic acid<p>digoxin increases and ethacrynic acid decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>ethacrynic acid increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor. Hypokalemia increases digoxin effects.</p></li><li>ethotoin<p>ethotoin will decrease the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>etodolac<p>etodolac and digoxin both increase  serum potassium. Use Caution/Monitor.</p></li><li>etoricoxib<p>etoricoxib and digoxin both increase  serum potassium. Use Caution/Monitor.</p></li><li>etravirine<p>etravirine increases levels of digoxin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Potential for increased toxicity. .</p></li><li>ezogabine<p>ezogabine increases levels of digoxin by decreasing renal clearance. Use Caution/Monitor. Active metabolite, NAMR, may inhibit the renal tubular secretion. Monitor digoxin levels.</p></li><li>famciclovir<p>famciclovir increases levels of digoxin by unspecified interaction mechanism. Use Caution/Monitor. Coadministration increases digoxin Cmax by ~19%.</p></li><li>felodipine<p>felodipine will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>fenbufen<p>fenbufen and digoxin both increase  serum potassium. Use Caution/Monitor.</p></li><li>fenoprofen<p>fenoprofen and digoxin both increase  serum potassium. Use Caution/Monitor.</p></li><li>fleroxacin<p>fleroxacin will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>flibanserin<p>flibanserin increases levels of digoxin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Increase monitoring of concentrations of drugs transported by P-gp that have a narrow therapeutic index if coadministered with flibanserin.</p></li><li>flucloxacillin<p>flucloxacillin will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>flurbiprofen<p>flurbiprofen and digoxin both increase  serum potassium. Use Caution/Monitor.</p></li><li>fluvastatin<p>digoxin increases toxicity of fluvastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>formoterol<p>digoxin increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>fosfomycin<p>fosfomycin will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>fosinopril<p>fosinopril increases levels of digoxin by unspecified interaction mechanism. Use Caution/Monitor.</p></li><li>fosphenytoin<p>fosphenytoin will decrease the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>furosemide<p>digoxin increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>furosemide increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor. Hypokalemia increases digoxin effects.</p></li><li>gemifloxacin<p>gemifloxacin will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>gentamicin<p>gentamicin will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>digoxin increases and gentamicin decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>glycopyrrolate<p>glycopyrrolate increases levels of digoxin by unknown mechanism. Use Caution/Monitor.</p></li><li>glycopyrrolate inhaled<p>glycopyrrolate inhaled increases levels of digoxin by unknown mechanism. Use Caution/Monitor.</p></li><li>hawthorn<p>hawthorn increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>hydrochlorothiazide<p>digoxin will increase the level or effect of hydrochlorothiazide by  basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.<span><br><br></span>digoxin increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>hydrochlorothiazide increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor. Hypokalemia increases digoxin effects.</p></li><li>ibuprofen<p>ibuprofen and digoxin both increase  serum potassium. Use Caution/Monitor.</p></li><li>imidapril<p>imidapril increases levels of digoxin by unspecified interaction mechanism. Use Caution/Monitor.</p></li><li>imipenem/cilastatin<p>imipenem/cilastatin will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>indapamide<p>digoxin increases and indapamide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>indapamide increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor. Hypokalemia increases digoxin effects.</p></li><li>indinavir<p>indinavir will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>indomethacin<p>indomethacin and digoxin both increase  serum potassium. Use Caution/Monitor.</p></li><li>irbesartan<p>irbesartan and digoxin both increase  serum potassium. Use Caution/Monitor.</p></li><li>isoproterenol<p>digoxin increases and isoproterenol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>itraconazole<p>itraconazole will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.<span><br><br></span>itraconazole increases levels of digoxin by enhancing GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>itraconazole increases levels of digoxin by decreasing renal clearance. Use Caution/Monitor.</p></li><li>ivabradine<p>ivabradine, digoxin.
Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Most patients receiving ivabradine will also be treated with a beta-blocker. The risk of bradycardia increases with  coadministration of drugs that slow heart rate (eg, digoxin, amiodarone, beta-blockers). Monitor heart rate in patients taking ivabradine with other negative chronotropes.</p></li><li>kanamycin<p>kanamycin will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>ketoconazole<p>ketoconazole will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>ketoprofen<p>ketoprofen and digoxin both increase  serum potassium. Use Caution/Monitor.</p></li><li>ketorolac<p>ketorolac and digoxin both increase  serum potassium. Use Caution/Monitor.</p></li><li>ketorolac intranasal<p>ketorolac intranasal and digoxin both increase  serum potassium. Use Caution/Monitor.</p></li><li>labetalol<p>labetalol and digoxin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>labetalol increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor. Enhanced bradycardia.</p></li><li>lansoprazole<p>lansoprazole increases toxicity of digoxin by Other (see comment). Use Caution/Monitor. 
Comment: Prolonged use of PPIs may cause hypomagnesemia and increase risk for digoxin toxicity.</p></li><li>lapatinib<p>lapatinib will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>ledipasvir/sofosbuvir<p>ledipasvir/sofosbuvir will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely.</p></li><li>levalbuterol<p>digoxin increases and levalbuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>levofloxacin<p>levofloxacin will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>levothyroxine<p>levothyroxine decreases effects of digoxin by unknown mechanism. Use Caution/Monitor.</p></li><li>linezolid<p>linezolid will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>liothyronine<p>liothyronine decreases effects of digoxin by unknown mechanism. Use Caution/Monitor.</p></li><li>lisinopril<p>lisinopril increases levels of digoxin by unspecified interaction mechanism. Use Caution/Monitor.</p></li><li>lomitapide<p>lomitapide increases levels of digoxin by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Consider reducing dose when used concomitantly with lomitapide.</p></li><li>loratadine<p>loratadine will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>lornoxicam<p>lornoxicam and digoxin both increase  serum potassium. Use Caution/Monitor.</p></li><li>losartan<p>losartan and digoxin both increase  serum potassium. Use Caution/Monitor.</p></li><li>lumacaftor/ivacaftor<p>lumacaftor/ivacaftor, digoxin. P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Lumacaftor has the potential to both inhibit and induce P-gp. Additionally, a clinical study with ivacaftor monotherapy showed that ivacaftor is a weak inhibitor of P-gp.</p></li><li>lymecycline<p>lymecycline will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>meclofenamate<p>meclofenamate and digoxin both increase  serum potassium. Use Caution/Monitor.</p></li><li>mefenamic acid<p>mefenamic acid and digoxin both increase  serum potassium. Use Caution/Monitor.</p></li><li>meloxicam<p>meloxicam and digoxin both increase  serum potassium. Use Caution/Monitor.</p></li><li>memantine<p>digoxin will increase the level or effect of memantine by  basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>meropenem<p>meropenem will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>metaproterenol<p>digoxin increases and metaproterenol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>metformin<p>digoxin, metformin.
Either increases levels of the other by basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor. Measure serum digoxin concentrations before initiating metformin. Monitor patients who take both metformin and digoxin for possible digoxin toxicity and lactic acidosis. Reduce the digoxin and/or metformin dose as necessary.</p></li><li>methotrexate<p>methotrexate decreases levels of digoxin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Serum levels of digoxin may be reduced and actions may be decreased. Monitor patient for signs of reduction in pharmacologic effect of digoxin and increase digoxin dose if necessary. Serum level monitoring may facilitate tailoring dosage.</p></li><li>methyclothiazide<p>digoxin will increase the level or effect of methyclothiazide by  basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.<span><br><br></span>digoxin increases and methyclothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.  .<span><br><br></span>methyclothiazide increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor. Hypokalemia increases digoxin effects.</p></li><li>metipranolol ophthalmic<p>metipranolol ophthalmic increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>metoclopramide<p>metoclopramide decreases levels of digoxin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>metolazone<p>digoxin increases and metolazone decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>metolazone increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor. Hypokalemia increases digoxin effects.</p></li><li>metoprolol<p>metoprolol and digoxin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>metoprolol increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor. Enhanced bradycardia.</p></li><li>metronidazole<p>metronidazole will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>midazolam<p>midazolam will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Elevated digoxin serum levels associated with toxicity have been reported. </p></li><li>midodrine<p>digoxin will increase the level or effect of midodrine by  basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>mineral oil<p>mineral oil decreases levels of digoxin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>minocycline<p>minocycline will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>mirabegron<p>mirabegron will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>moexipril<p>moexipril increases levels of digoxin by unspecified interaction mechanism. Use Caution/Monitor.</p></li><li>moxifloxacin<p>moxifloxacin will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>nabumetone<p>nabumetone and digoxin both increase  serum potassium. Use Caution/Monitor.</p></li><li>nadolol<p>nadolol and digoxin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>nadolol increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor. Enhanced bradycardia.</p></li><li>nafcillin<p>nafcillin will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>naproxen<p>naproxen and digoxin both increase  serum potassium. Use Caution/Monitor.</p></li><li>nebivolol<p>nebivolol and digoxin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>nebivolol increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor. Enhanced bradycardia.</p></li><li>nefazodone<p>nefazodone will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>neomycin po<p>neomycin po will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>neomycin po decreases levels of digoxin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>netilmicin<p>netilmicin will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>nicardipine<p>nicardipine will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>nifedipine<p>nifedipine will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Nifedipine  may decrease digoxin clearance, increasing plasma concentrations and the risk of toxicity. Adjust the digoxin dose as needed.</p></li><li>nilotinib<p>nilotinib will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>nitrofurantoin<p>nitrofurantoin will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>norepinephrine<p>digoxin increases and norepinephrine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>norfloxacin<p>norfloxacin will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>ofloxacin<p>ofloxacin will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>digoxin will increase the level or effect of ofloxacin by  basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>olmesartan<p>olmesartan and digoxin both increase  serum potassium. Use Caution/Monitor.</p></li><li>ombitasvir/paritaprevir/ritonavir<p>ombitasvir/paritaprevir/ritonavir will increase the level or effect of digoxin by  Other (see comment). Use Caution/Monitor. Paritaprevir inhibits OATP1B1, OATP1B3, and BCRP. Ritonavir inhibits BCRP. Caution if coadministered with drugs that are substrates of these transporters. Decrease digoxin dose by 30-50%. Appropriate monitoring of serum digoxin levels is recommended.<span><br><br></span>ombitasvir/paritaprevir/ritonavir will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Decrease digoxin dose by 30-50%. Appropriate monitoring of serum digoxin levels is recommended.</p></li><li>omeprazole<p>omeprazole increases toxicity of digoxin by Other (see comment). Use Caution/Monitor. 
Comment: Prolonged use of PPIs may cause hypomagnesemia and increase risk for digoxin toxicity.</p></li><li>oxaprozin<p>oxaprozin and digoxin both increase  serum potassium. Use Caution/Monitor.</p></li><li>oxymetazoline topical<p>oxymetazoline topical decreases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor. Digoxin reduces catecholamine reuptake at nerve terminals, rendering blood vessels more sensitive to endogenous or exogenous catecholamines.</p></li><li>oxytetracycline<p>oxytetracycline will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>pantoprazole<p>pantoprazole increases toxicity of digoxin by Other (see comment). Use Caution/Monitor. 
Comment: Prolonged use of PPIs may cause hypomagnesemia and increase risk for digoxin toxicity.</p></li><li>parecoxib<p>parecoxib and digoxin both increase  serum potassium. Use Caution/Monitor.</p></li><li>paricalcitol<p>paricalcitol increases toxicity of digoxin by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>paromomycin<p>paromomycin will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>penbutolol<p>penbutolol and digoxin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>penbutolol increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor. Enhanced bradycardia.</p></li><li>perindopril<p>perindopril increases levels of digoxin by unspecified interaction mechanism. Use Caution/Monitor.</p></li><li>phenobarbital<p>phenobarbital will decrease the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>phenytoin<p>phenytoin will decrease the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>pindolol<p>pindolol and digoxin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>pindolol increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor. Enhanced bradycardia.</p></li><li>pirbuterol<p>digoxin increases and pirbuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>piroxicam<p>piroxicam and digoxin both increase  serum potassium. Use Caution/Monitor.</p></li><li>pitavastatin<p>digoxin increases toxicity of pitavastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>pivmecillinam<p>pivmecillinam will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>ponatinib<p>ponatinib increases levels of digoxin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>posaconazole<p>posaconazole increases levels of digoxin by decreasing metabolism. Use Caution/Monitor.</p></li><li>potassium acid phosphate<p>potassium acid phosphate and digoxin both increase  serum potassium. Modify Therapy/Monitor Closely.</p></li><li>potassium chloride<p>potassium chloride and digoxin both increase  serum potassium. Modify Therapy/Monitor Closely.</p></li><li>pramipexole<p>digoxin will increase the level or effect of pramipexole by  basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>pravastatin<p>digoxin increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>procarbazine<p>procarbazine decreases levels of digoxin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>propranolol<p>propranolol and digoxin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>propranolol increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor. Enhanced bradycardia.</p></li><li>quercetin<p>quercetin will decrease the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>quinapril<p>quinapril increases levels of digoxin by unspecified interaction mechanism. Use Caution/Monitor.</p></li><li>quinine<p>digoxin will increase the level or effect of quinine by  basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>quinupristin/dalfopristin<p>quinupristin/dalfopristin will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>rabeprazole<p>rabeprazole increases toxicity of digoxin by Other (see comment). Use Caution/Monitor. 
Comment: Prolonged use of PPIs may cause hypomagnesemia and increase risk for digoxin toxicity.</p></li><li>ramipril<p>ramipril increases levels of digoxin by unspecified interaction mechanism. Use Caution/Monitor.</p></li><li>ranolazine<p>ranolazine will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.<span><br><br></span>ranolazine increases levels of digoxin by decreasing metabolism. Use Caution/Monitor. Ranolazine inhibits P glycoprotein.</p></li><li>regorafenib<p>regorafenib will decrease the level or effect of digoxin by  inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Chemotherapy may decrease absorption of digoxin; monitor levels and adjust digoxin dose accordingly</p></li><li>reserpine<p>reserpine will decrease the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>rifabutin<p>rifabutin decreases levels of digoxin by increasing metabolism. Use Caution/Monitor.</p></li><li>rifampin<p>rifampin will decrease the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Reduced digoxin serum concentrations, possibly with a suboptimal therapeutic response, may be seen.  <span><br><br></span>rifampin decreases levels of digoxin by increasing metabolism. Use Caution/Monitor.</p></li><li>rifapentine<p>rifapentine decreases levels of digoxin by increasing metabolism. Use Caution/Monitor.</p></li><li>ritonavir<p>ritonavir will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Plasma concentrations and pharmacologic effects of digoxin may be increased by ritonavir.  Monitor for increased effects of digoxin.<span><br><br></span>ritonavir increases levels of digoxin by decreasing renal clearance. Use Caution/Monitor.<span><br><br></span>ritonavir increases levels of digoxin by decreasing hepatic clearance. Use Caution/Monitor.</p></li><li>rolapitant<p>rolapitant will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Monitor for adverse reactions when unable to avoid coadministration with narrow therapeutic index P-gp substrates.</p></li><li>rosuvastatin<p>digoxin increases toxicity of rosuvastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>sacubitril/valsartan<p>sacubitril/valsartan and digoxin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>digoxin will increase the level or effect of sacubitril/valsartan by  Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure</p></li><li>salicylates (non-asa)<p>salicylates (non-asa) and digoxin both increase  serum potassium. Use Caution/Monitor.</p></li><li>salmeterol<p>digoxin increases and salmeterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>salsalate<p>salsalate and digoxin both increase  serum potassium. Use Caution/Monitor.</p></li><li>saquinavir<p>saquinavir increases levels of digoxin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Potential for increased toxicity. .</p></li><li>senna<p>senna increases toxicity of digoxin by Other (see comment). Use Caution/Monitor. 
Comment: Increased risk of cardiac toxicity due to K+ depletion.</p></li><li>sevelamer<p>sevelamer decreases levels of digoxin by increasing elimination. Use Caution/Monitor.</p></li><li>simeprevir<p>simeprevir increases levels of digoxin by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Simeprevir inhibits OATP1B1/3 and P-glycoprotein (P-gp) transporters; may increase plasma concentrations of substrates for OATP1B1/3 and P-gp transport.</p></li><li>simvastatin<p>simvastatin will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.<span><br><br></span>digoxin increases toxicity of simvastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>sirolimus<p>sirolimus will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>sodium picosulfate/magnesium oxide/anhydrous citric acid<p>sodium picosulfate/magnesium oxide/anhydrous citric acid decreases levels of digoxin by cation binding in GI tract. Use Caution/Monitor. Take at least 2 hours before and not less than 6 hours after administration of sodium picosulfate, magnesium oxide and anhydrous citric acid to avoid magnesium chelation&nbsp;.</p></li><li>sofosbuvir/velpatasvir<p>sofosbuvir/velpatasvir will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Velpatasvir inhibits P-gp. Monitor digoxin levels if coadministered. Refer to digoxin prescribing information for monitoring and dose modification recommendations for digoxin concentration increases of &lt;50%.</p></li><li>sotalol<p>sotalol and digoxin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>sotalol increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor. Enhanced bradycardia.</p></li><li>spironolactone<p>spironolactone will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Spironolactone  has been shown to increase the half-life of digoxin and subsequent toxicity may occur. Monitor carefully during coadministration<span><br><br></span>spironolactone and digoxin both increase  serum potassium. Modify Therapy/Monitor Closely.<span><br><br></span>spironolactone, digoxin. Mechanism: decreasing renal clearance. Use Caution/Monitor. False digoxin assay results may be obtained.<span><br><br></span>spironolactone increases levels of digoxin by Other (see comment). Use Caution/Monitor. 
Comment: Spironolactone may cause false elevation of digoxin assay.</p></li><li>st john's wort<p>st john's wort will decrease the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.<span><br><br></span>st john's wort decreases levels of digoxin by increasing metabolism. Use Caution/Monitor.</p></li><li>streptomycin<p>streptomycin will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>succinylcholine<p>digoxin and succinylcholine both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>succinylcholine, digoxin. Mechanism: unknown. Use Caution/Monitor. Increased risk of cardiac arrhythmias.</p></li><li>sulfadiazine<p>sulfadiazine will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>sulfamethoxazole<p>sulfamethoxazole will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>sulfamethoxazole will increase the level or effect of digoxin by  basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>sulfasalazine<p>sulfasalazine and digoxin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>sulfasalazine decreases levels of digoxin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Sulfasalazine &gt;2 g/day.</p></li><li>sulfisoxazole<p>sulfisoxazole will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>sulindac<p>sulindac and digoxin both increase  serum potassium. Use Caution/Monitor.</p></li><li>suvorexant<p>suvorexant will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Suvorexant may cause a slight increase in digoxin levels</p></li><li>tacrolimus<p>tacrolimus will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>teduglutide<p>teduglutide increases levels of digoxin by Other (see comment). Use Caution/Monitor. 
Comment: Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary.</p></li><li>teicoplanin<p>teicoplanin will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>telaprevir<p>telaprevir increases levels of digoxin by Other (see comment). Use Caution/Monitor. 
Comment: Concentrations of digoxin were increased when co-administered with telaprevir. The lowest dose of digoxin should be initially prescribed. The serum digoxin concentrations should be monitored and used for titration of digoxin dose to obtain the desired clinical effect.</p></li><li>telithromycin<p>telithromycin will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>telmisartan<p>telmisartan and digoxin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>telmisartan increases levels of digoxin by unknown mechanism. Use Caution/Monitor.</p></li><li>temocillin<p>temocillin will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>tenofovir df<p>tenofovir df increases levels of digoxin by decreasing renal clearance. Use Caution/Monitor. Potential for increased toxicity. .</p></li><li>terbutaline<p>digoxin increases and terbutaline decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>teriparatide<p>teriparatide increases toxicity of digoxin by Other (see comment). Use Caution/Monitor. 
Comment: Transient hypercalcemia may predispose to digoxin toxicity (rare case reports).</p></li><li>tetracycline<p>tetracycline will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>thyroid desiccated<p>thyroid desiccated decreases effects of digoxin by unknown mechanism. Use Caution/Monitor.</p></li><li>ticagrelor<p>ticagrelor increases levels of digoxin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Ticagrelor inhibits P-glycoprotein transporter. Monitor digoxin levels with initiation of or any change in ticagrelor therapy.</p></li><li>ticarcillin<p>ticarcillin will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>tigecycline<p>tigecycline will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>timolol<p>timolol and digoxin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>timolol increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor. Enhanced bradycardia.</p></li><li>tipranavir<p>tipranavir increases levels of digoxin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Potential for increased toxicity. .</p></li><li>tobramycin<p>tobramycin will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>tolfenamic acid<p>tolfenamic acid and digoxin both increase  serum potassium. Use Caution/Monitor.</p></li><li>tolmetin<p>tolmetin and digoxin both increase  serum potassium. Use Caution/Monitor.</p></li><li>tolvaptan<p>tolvaptan will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.<span><br><br></span>digoxin and tolvaptan both increase  serum potassium. Use Caution/Monitor.</p></li><li>torsemide<p>digoxin increases and torsemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>torsemide increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor. Hypokalemia increases digoxin effects.</p></li><li>trandolapril<p>trandolapril increases levels of digoxin by unspecified interaction mechanism. Use Caution/Monitor.</p></li><li>trazodone<p>trazodone will decrease the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.<span><br><br></span>trazodone increases levels of digoxin by unspecified interaction mechanism. Use Caution/Monitor.</p></li><li>triamterene<p>digoxin will increase the level or effect of triamterene by  basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.<span><br><br></span>triamterene and digoxin both increase  serum potassium. Modify Therapy/Monitor Closely.</p></li><li>trimagnesium citrate anhydrous<p>digoxin decreases effects of trimagnesium citrate anhydrous by increasing renal clearance. Use Caution/Monitor.</p></li><li>trimethoprim<p>trimethoprim will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.<span><br><br></span>digoxin will increase the level or effect of trimethoprim by  basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>trospium chloride<p>digoxin, trospium chloride.
Either increases levels of the other by decreasing renal clearance. Use Caution/Monitor.</p></li><li>ulipristal<p>ulipristal increases levels of digoxin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>valsartan<p>digoxin will increase the level or effect of valsartan by  Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure<span><br><br></span>valsartan will increase the level or effect of digoxin by  decreasing renal clearance. Use Caution/Monitor. Monitor digoxin levels closely when coadministered with drugs that may decrease glomerular filtration or tubular secretion.</p></li><li>vancomycin<p>vancomycin will increase the level or effect of digoxin by  altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>vemurafenib<p>vemurafenib increases levels of digoxin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>verapamil<p>verapamil will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Toxicity characterized by gastrointestinal and neuropsychiatric symptoms, and cardiac arrhythmias may result.<span><br><br></span>digoxin will increase the level or effect of verapamil by  basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>vincristine<p>vincristine decreases levels of digoxin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>vincristine liposomal<p>vincristine liposomal decreases levels of digoxin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>vitamin d<p>vitamin d increases toxicity of digoxin by Other (see comment). Use Caution/Monitor. 
Comment: Vitamin D may cause hypercalcemia which may affect the actions of digoxin and/or lead to cardiac arrhythmias.</p></li>